Live Breaking News & Updates on மான்ட்ரியல் ஆரோக்கியம் புதுமைகள் ஒருங்கிணைத்தல் மையம்

Stay informed with the latest breaking news from மான்ட்ரியல் ஆரோக்கியம் புதுமைகள் ஒருங்கிணைத்தல் மையம் on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in மான்ட்ரியல் ஆரோக்கியம் புதுமைகள் ஒருங்கிணைத்தல் மையம் and stay connected to the pulse of your community

Results of the COLCORONA study published in The Lancet Respiratory Medicine - News Makers

Results of the COLCORONA study published in The Lancet Respiratory Medicine - News Makers
newsmakers.pk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsmakers.pk Daily Mail and Mail on Sunday newspapers.

South-africa , Montreal , Quebec , Canada , United-states , America , Canadian , Sophie-desmarais , Jean-claude-tardif , Yves-rosenberg , Montreal-heart-institute , Mastercard

Results of the COLCORONA study published in The Lancet Respiratory Medicine Colchicine could be considered as a treatment for non-hospitalized patients diagnosed with COVID-19 by PCR test and at risk of complications

MONTREAL, May 28, 2021 (GLOBE NEWSWIRE) — The Montreal Heart Institute (MHI) announces that the COLCORONA study results are published in The Lancet…

South-africa , Montreal , Quebec , Canada , United-states , America , Canadian , Sophie-desmarais , Jean-claude-tardif , Camille-turbide , Yves-rosenberg , Montreal-heart-institute

Results of the COLCORONA study published in The Lancet Respiratory Medicine | Comunicados | Edición USA

Results of the COLCORONA study published in The Lancet Respiratory Medicine | Comunicados | Edición USA
efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.

South-africa , Montreal , Quebec , Canada , United-states , America , Canadian , Sophie-desmarais , Jean-claude-tardif , Yves-rosenberg , Montreal-heart-institute , Mastercard

Montreal Heart Institute: Results of the COLCORONA study published in The Lancet Respiratory Medicine

Colchicine could be considered as a treatment for non-hospitalized patients diagnosed with COVID-19 by PCR test and at risk of complicationsMONTREAL, May 28, 2021 (GLOBE NEWSWIRE) -- The Montreal Heart

South-africa , Montreal , Quebec , Canada , United-states , America , Canadian , Sophie-desmarais , Jean-claude-tardif , Kostenloser-wertpapierhandel , Camille-turbide , Yves-rosenberg

Results of the COLCORONA study published in The Lancet Respiratory Medicine

Results of the COLCORONA study published in The Lancet Respiratory Medicine
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South-africa , Montreal , Quebec , Canada , United-states , America , Canadian , Sophie-desmarais , Jean-claude-tardif , Yves-rosenberg , Montreal-heart-institute , Mastercard

AlphaGalileo > Item Display

AlphaGalileo > Item Display
alphagalileo.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alphagalileo.org Daily Mail and Mail on Sunday newspapers.

South-africa , Montreal , Quebec , Canada , United-states , America , Canadian , Sophie-desmarais , Jean-claude-tardif , Yves-rosenberg , Montreal-heart-institute , Mastercard

Colchicine reduces the risk of COVID-19-related complications Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients

Article content
MONTREAL, Jan. 22, 2021 (GLOBE NEWSWIRE) — The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo. This result obtained for the global study population of 4488 patients approached statistical significance. The analysis of the 4159 patients in whom the diagnosis of COVID-19 was proven by a naso-pharyngeal PCR test has shown that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization compared to placebo. In these patients with a proven diagnosis of COVID-19, colchicine reduced hospitalizations by 25%, the need for mechanical ventilation by 50%, and deaths by 44%. This major scientific discovery makes colchicine the world’s first oral drug that could be used to treat non-hospitalized patients with COVID-19.

Montreal , Quebec , Canada , South-africa , United-states , America , Canadian , Sophie-desmarais , Jean-claude-tardif , Camille-turbide , Christy-maginn , Montreal-heart-institute

Investegate |Montreal Heart Institute Announcements | Montreal Heart Institute: Colchicine reduces the risk of COVID-19-related complications

Investegate announcements from Montreal Heart Institute, Colchicine reduces the risk of COVID-19-related complications

Montreal , Quebec , Canada , South-africa , United-states , America , Canadian , Sophie-desmarais , Jean-claude-tardif , Camille-turbide , Christy-maginn , Montreal-heart-institute

Colchicine reduces the risk of COVID-19-related complications

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Colchicine reduces the risk of COVID-19-related complications
Montreal Heart InstituteJanuary 23, 2021 GMT
MONTREAL, Jan. 22, 2021 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo. This result obtained for the global study population of 4488 patients approached statistical significance. The analysis of the 4159 patients in whom the diagnosis of COVID-19 was proven by a naso-pharyngeal PCR test has shown that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization compared to placebo. In these patients with a proven diagnosis of COVID-19, colchicine reduced hospitalizations by 25%, the need for mechanical ventilation by 50%, and deaths by 44%. This major scientific discovery makes colchicine the world’s first oral drug that could be used to treat non-hospitalized patients with COVID-19.

Montreal , Quebec , Canada , South-africa , United-states , America , Canadian , Sophie-desmarais , Jean-claude-tardif , Camille-turbide , Christy-maginn , Montreal-heart-institute